377 results on '"Origa, Raffaella"'
Search Results
2. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years
3. Deferasirox film‐coated tablet‐associated ulcerative colitis: An emerging pattern in thalassemia patients?
4. Unplanned pregnancy in women with beta‐thalassaemia treated with luspatercept
5. Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization
6. Pretransfusion hemoglobin level and mortality in adults with transfusion-dependent β-thalassemia
7. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial
8. Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study
9. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major
10. 'Phenoconversion' in adult patients with β‐thalassemia.
11. Hematological phenotypes in children according to the α-globin genotypes
12. Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited
13. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia
14. Pretransfusion hemoglobin level and mortality in adults with transfusion-dependent β-thalassemia
15. Management of the Sickle Cell Trait: An Opinion by Expert Panel Members
16. Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending
17. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
18. Nephrological Complications in Hemoglobinopathies: SITE Good Practice.
19. Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
20. Reply to “Hepatocellular carcinoma in thalassemia and other hemoglobinopathies”
21. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
22. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
23. Thalassemia major between liver and heart: Where we are now
24. IFNL3 polymorphisms and HCV infection in patients with beta thalassemia
25. Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021
26. Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia
27. Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion‐dependent thalassemia
28. Crushed Deferasirox Film‐Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis: Results From a Single‐Arm, Interventional Phase 4 Study (MIMAS)
29. Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
30. EPO and hepcidin plasma concentrations in blood donors and β‐thalassemia intermedia are not related to commercially tested plasma ERFE concentrations
31. Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021.
32. Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies
33. Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy
34. Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia
35. Hemoglobinopathies and Cancer: Preliminary Results of an Italian Multicenter Experience
36. Deferasirox and children: From clinical trials to the real world
37. The Problem of Borderline Hemoglobin A2 Levels in the Screening for β-Thalassemia Carriers in Sardinia
38. Changing patterns of thalassaemia in Italy: a WebThal perspective
39. Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000–2015
40. Thalassemia Major: Who Is Afraid of Serum Ferritin below 500 μg/l?
41. Investigating the Alpha1NcoI Mutation
42. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia
43. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study
44. Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm
45. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
46. α-Globin Gene Quadruplication and Heterozygous β-Thalassemia: A Not So Rare Cause of Thalassemia Intermedia
47. Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort
48. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major
49. Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen
50. Additional file 1 of Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.